Media Coverage

Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

The 23rd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) will be taking place virtually from May 12-15, 2020. Intellia Therapeutics Inc., a company specializing in genome editing using CRISPR/Cas9, announced that five poster abstracts have been accepted for presentation at this meeting. One specific poster, titled "In Vivo Model Development for Genome-Edited T Cell Therapeutics", demonstrates the use of improved murine models...  Read More

Betting on the Bug: The Microbiome's Impact on Drug Efficacy

Betting on the Bug: The Microbiome's Impact on Drug Efficacy

Taconic's Dr. Alexander Maue recently authored a follow-up article for International Biopharmaceutical Industry (IBI) to his original comment on how the microbiome can improve reproducibility and translatability of animal models. In part two, he elaborates on how the microbiome can impact drug efficacy and what types of mouse models are being developed to further immuno-oncology research. Read the complete article at: biopharmaceuticalmedia.com...  Read More

Bitten By the Bug - A Flurry of Investments Fuel Microbiome Drug Discovery

Bitten By the Bug - A Flurry of Investments Fuel Microbiome Drug Discovery

Recent research into the microbiome demonstrates that the composition of gut microbiota influences the development and progression of disease. However, more research is needed to fully strengthen this connection. Taconic's Dr. Alexander Maue recently authored an article for Drug Discovery World depicting the investment landscape of biotech and pharmaceutical companies in the microbiome field. Dr. Maue describes how the number of IPOs, mergers & acquisitions, collaborations, and...  Read More

Using Sales, Inventory, and Operations Planning to Support the 3Rs

Using Sales, Inventory, and Operations Planning to Support the 3Rs

SIOP is an important process for many companies, and of prime importance for mouse model generation. Taconic's Terry Receveur was recently featured in AALAS discussing this process, and how it supports the 3Rs of animal research: Replacement, Reduction, and Refinement. The goal of SIOP is to develop a plan for sales, production, inventory, new product development, strategic initiatives, and financials. Read the complete article at: aalas.org...  Read More

Getting Precise: How Humanized Models Aid in Biologics Drug Discovery

Getting Precise: How Humanized Models Aid in Biologics Drug Discovery

In a recent article for Drug Target Review, Taconic's Dr. Paul Volden emphasizes how humanized immune system (HIS) mouse models have enabled the development of numerous immunotherapies. HIS models contain human immune cells and can offer more translatability in drug discovery and development than genetically engineered models. There are now a wide-variety of humanized mice available from animal model vendors, including the severely immunodeficient CIEA NOG mouse...  Read More

Cancer labs reach beyond exhausted T cells

Cancer labs reach beyond exhausted T cells

The concept of T cell exhaustion and the associated immune response has become a priority for immuno-oncology researchers. Taconic's Dr. Janell Richardson was recently interviewed by Nature Methods to elaborate on how mouse models are helping researchers understand the complex processes involved in tumor-immune system interactions. The tumor microenvironment, cytokine expression, and cross-talk between immune system cells all play vital roles in understanding more how tumors evade...  Read More

Animal Models Evolve to Satisfy Emerging Needs

Animal Models Evolve to Satisfy Emerging Needs

Genetic Engineering & Biotechnology News recently published an article discussing the progression of advanced animal models for drug development research efforts. To address these developing needs, Taconic's Dr. Michael Seiler describes the differences between traditional inbred models and genetically engineered humanized immune system mice. Multiple humanized mouse models have been created in recent years, enabling researchers to conduct advanced studies in mice with humanized immune systems. "Traditional...  Read More

Guest Commentary: The unique IP landscape of CRISPR/Cas9-edited animal models

Guest Commentary: The unique IP landscape of CRISPR/Cas9-edited animal models

The IP landscape surrounding the use of the CRISPR/Cas9 technology (and variants of it) can pose challenges for model generation. In a recent article published in DDN, Taconic Biosciences' Dr. Caroline Horizny explains the various CRISPR/Cas9 patents and the implications of obtaining patent rights when creating a new animal model for preclinical research: "The CRISPR/Cas9 system, and variants of it, allows for in-vivo modifications including gene knockouts,...  Read More

Rodents to the rescue

Rodents to the rescue

An article recently published in DDN highlights Taconic Biosciences's new diet-induced NASH mouse model and its importance for preclinical liver disease research. The NASH B6 is available commercially off-the-shelf and available immediately for NAFLD and NASH studies. This level of access enables researchers to test and develop new therapeutics sooner, by skipping the twenty-six weeks needed for other mouse models to develop NASH symptoms once placed on...  Read More

A model summer: Preclinical research developments rise with the temperature

A model summer: Preclinical research developments rise with the temperature

Two of Taconic Biosciences's newest products are highlighted in a recent article published in Outsourcing-Pharma. The first, TruBIOME™, is a comprehensive solution to increase reproducibility in mouse models through custom microbial associations. The second is the launch of Taconic's new commercial diet-induced NASH mouse model, which will enable researchers to obtain a model faster for preclinical studies: "As summer heated up, the pharmaceutical industry saw major developments...  Read More